Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders

Similar documents
Reducing opioid overdose mortality: role of communityadministered

1/23/2015. Disclosure. Overview. A National Response to a Public Health Crisis Opioid Overdose and the Changing Spectrum of Care

4/10/2016. Legal & Policy Approaches to Reducing Opioid Poisonings. Overview. Background. Health Directors Legal Conference April 19, 2016

10/20/14& the administration of nasal naloxone by school nurses. for nasal naloxone

Naloxone: Preventing Opioid Overdose in the Community. Sharon Stancliff, MD Medical Director Harm Reduction Coalition

Journal Club: Naloxone Programs in the Community and Their Success to Decrease Overdoses from Opioids

The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded

Optimizing Safety in Patients with Addictions

NARCAN: THE HISTORY, APPLICATIONS AND FUTURE

Addressing the Opioid Epidemic through a Public Health Lens

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals

Naloxone (Narcan) Initiatives and the Court System

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

Opioid Harm Reduction

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies

Naloxone: What You Need to Know About Overdose Reversal In the Midst of an Opioid Epidemic

Opioid Overdose Education and Naloxone Distribution

Naloxone for Emergency Administration: A 2017 Update On FDA Guidance

A Bill Regular Session, 2015 SENATE BILL 880

Naloxone for Opioid Safety

Workshop: A roadmap for overdose prevention policies: where do you fit?

Law Enforcement Naloxone Training Florida Department of Children and Families. Office of Substance Abuse and Mental Health

Clackamas County Overdose Prevention and Recovery Support Projects. Apryl L. Herron, MPH Clackamas County Public Health Division

Touchpoints Prior to Opioid Overdose Death

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.

Naloxone Access Statutes

2018 APM Winter Meeting San Antonio, TX

HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC

TN Opioid Program. Erica Schlesinger, Pharm.D

Welcome to the Opioid Overdose Prevention Project

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

Opioid Prescription and Illicit Drug Overdoses: On the Rise

Protocol For: Personally Furnishing Naloxone. Update Log

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

Responding to the Opioid Epidemic

Opportunities for Engaging Partners to Prevent Opioid Overdose-related Deaths

Optimizing Safety in People with Addictions

Maryland s Good Samaritan Law

Revised 16 February, of 7

Evaluations. Viewer Call-In. Guest Speakers. What s New in AIDS/HIV? Phone: Fax: Thank You to our Sponsors

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

Naloxone Non-Patient Specific Prescription and Pharmacist Dispensing Protocol, New York City

Anyone Can Become Addicted. Anyone.

Harm Reduction. West Virginia Rural Health Conference, October 17, 2018

Drug Class Review: Opioid Reversal Agents

Presenters. Session Objectives. Session Overview. Cluster Investigations in Rural Wisconsin

Preventing overdose fatalities: The role of naloxone and of supervised injection facilities Sharon Stancliff, MD Medical Director Harm Reduction

Public Health Impacts of 2016 West Virginia Legislation

Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative

8.0 Take Home Naloxone

POWER TO HELP REVERSE AN OPIOID OVERDOSE

TITLE AUTHORS. Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy

There are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014

Combating Opiate Addiction

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Opportunities for Opioid Safety and Community-Based Overdose Management

Steve Alsum. The Grand Rapids Red Project. (616)

NARCAN? YOU CAN!: A LEGISLATIVE & CLINICAL UPDATE ON NALOXONE

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Naloxone Access Statutes

SULLIVAN COUNTY Drug Abuse Prevention Task Force

Drug Overdose Prevention Program (DOPP)

Take Home Naloxone: What Pharmacists Need to Know

Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING

IMPLEMENTATION OF A SHARED MEDICAL APPOINTMENT FOR OPIOID OVERDOSE EDUCATION AND NALOXONE KIT TRAINING FOR VETERANS Kristin A. Tallman, Pharm.

State Opioid Response (SOR) Grant

OPIATES WHAT'S THE PROBLEM?

Addressing the Opioid Epidemic Naloxone and its Role in Prevention of Opioid Overdose Death May 24, 2018

How to Save a Life: Naloxone for the Treatment of Opioid Overdose

Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. September 2016 TRANSCRIPT

Overdose Prevention, Recognition & Response Education Train-the-Trainer

ASSEMBLY, No STATE OF NEW JERSEY. 216th LEGISLATURE INTRODUCED MAY 15, 2014

PREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region

BRIEFING ON WHY AND HOW TO ADDRESS OVERDOSE IN GLOBAL FUND PROPOSALS

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Braintree Public Schools

The Criminal Justice Response to Opioid Trafficking in Michigan

Nevada Rural Opioid Overdose Reversal (NROOR) Program Overview and Update

Good Samaritan and Naloxone Bill Status Report Carryover 2016 and Special Sessions

Best Practices in Naloxone Treatment Programs for Opioid Overdose

Patient and Family Agreement on Opioids

Overdose follow-up interventions:

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Take-Home Naloxone for Opioid Overdose: Exploring the Legal, Policy and Practice Landscapes

The Nova Scotia Take Home Naloxone Program. Amanda Hudson-Frigault, MA NS THN Coordinator

Naloxone Information for Community Pharmacies in Georgia: What You Need to Know

PROPOSED AMENDMENTS TO HOUSE BILL 3440

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent

Naloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

Opioid Overdose Prevention for Law Enforcement and First Responders. Sponsored by the NC Office of EMS

Temple University Beasley School of Law. Project on Harm Reduction in the Health Care System

Orange County Heroin Task Force Implementation Update. George Ralls M.D. Director of Health & Public Safety Orange County Government

First Responder Naloxone Grant Webinar

Using Naloxone to Reduce the Number of Opioid Overdose Deaths Among Clackamas County Inmates Post-Release

Data Driven Strategies

Good Samaritan. State with this law in place: New Mexico, Washington, New York, Connecticut, Illinois (to be enforced June 1, 2012)

Transcription:

Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders Alexander Y. Walley, MD, MSc Boston University School of Medicine ThINC Bergen 2015 Conference on Overdose Awareness Tuesday, September 1, 2015 3:45-4:15pm

Disclosures Alexander Y. Walley, MD, MSc The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months: None My presentation will include discussion of off-label use of the following: Naloxone is FDA approved as an opioid antagonist Naloxone delivered as an intranasal spray with a mucosal atomizer device has not been FDA approved and is off label use

Enrollment locations: 2008-2014 Using, In Treatment, or In Recovery Non Users (family, friends, staff) Detox Drop-In Center Community Meeting Syringe Access Residential / 1/2 way house Methadone Clinic Inpatient / ED / Outpatient Home Visit / Shelter / Street Outreach Other Program Data 0 1000 2000 3000 4000 5000 6000 7000 8000 Program data from people with location reported: Users: 20,012 Non-Users: 10,415 Currently > 36,000 enrollees (28 per day) and > 5200 overdose rescues documented (5 per day)

Enrollee characteristics: 2006-2014 User n=21,296 Non-User n=11,016 Witnessed overdose ever 74% 40% Lifetime history of overdose 46% Received naloxone ever 39% Inpatient detox, past year 61% Incarcerated, past year 24% Reported at least one overdose rescue 9.2% 2.4% Program data

Opioid Overdose Related Deaths: Massachusetts 2004-2006 OEND programs 2006-07 2007-08 2009 Towns without Number of Deaths No Deaths 1-5 6-15 16-30 30+

Fatal opioid overdose rates reduced where OEND implemented Naloxone coverage per 100K 250 200 150 100 50 0 Opioid overdose death rate 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 27% reduction 46% reduction No coverage 1-100 ppl 100+ ppl Walley et al. BMJ 2013; 346: f174.

INPEDE OD Study Summary 1. Fatal OD rates were decreased in MA cities-towns where OEND was implemented and the more enrollment the lower the reduction 2. No clear impact on acute care utilization

Mainstreaming naloxone rescue kits

The AMA has been a longtime supporter of increasing the availability of Naloxone for patients, first responders and bystanders who can help save lives and has provided resources to bolster legislative efforts to increase access to this medication in several states. www.ama- assn.org/ama/pub/news/news/2014/2014-04-07- naxolene-product-approval.page APhA supports the pharmacist s role in selecting appropriate therapy and dosing and initiating and providing education about the proper use of opioid reversal agents to prevent opioid-related deaths due to overdose ASAM Board of Directors April 2010 Naloxone has been proven to be an effective, fast-acting, inexpensive and non-addictive opioid antagonist with minimal side effects... Naloxone can be administered quickly and effectively by trained professional and lay individuals who observe the initial signs of an opioid overdose reaction. www.pharmacist.com/policy/controlledsubstances-and-other-medications-potentialabuse-and-use-opioid-reversal-agents-2 www.asam.org/docs/publicy-policystatements/1naloxone-1-10.pdf 10

Law that limits liability and promotes help-seeking, third party prescribing Massachusetts - August 2012: Good Samaritan provision: Protects people who overdose or seek help for someone overdosing from being charged or prosecuted for drug possession Protection does not extend to trafficking or distribution charges Patient protection: A person acting in good faith may receive a naloxone prescription, possess naloxone and administer naloxone to an individual appearing to experience an opiate-related overdose. Prescriber protection: Naloxone or other opioid antagonist may lawfully be prescribed and dispensed to a person at risk of experiencing an opiate-related overdose or a family member, friend or other person in a position to assist a person at risk of experiencing an opiate-related overdose. For purposes of this chapter and chapter 112, any such prescription shall be regarded as being issued for a legitimate medical purpose in the usual course of professional practice.

Standing orders in Massachusetts 1. Standing order at DPH that permits the distribution of naloxone kits by public health workers 2. State wide protocol that permits EMTs and first responders to use naloxone during an overdose rescue 3. Pharmacy standing order that permits retail pharmacies to furnish naloxone to customers without a specific prescription Known as a collaborative practice agreement in many states 4. Inpatient/ emergency department standing orders that allow a hospital pharmacy to furnish naloxone to patients upon discharge 12

Training family members at support group meetings Bagley et al. Overdose Education and Naloxone Rescue Kits for Family Members of Individuals Who Use Opioids: Characteristics, Motivations, and Naloxone Use. Substance Abuse 2015.

Training family members at support group meetings Bagley et al. Overdose Education and Naloxone Rescue Kits for Family Members of Individuals Who Use Opioids: Characteristics, Motivations, and Naloxone Use. Substance Abuse 2015.

Police and Fire naloxone rescues in MA 2010-2014 Massachusetts DPH First Responder Pilot 350 300 250 200 150 100 50 0 Rescues and deaths, 2010-2014 318 160 111 8 67 2010 2011 2012 2013 2014 Signs of life, but died Dead on arrival Rescue

Withdrawal symptoms after naloxone rescue 2010-2014 Community naloxone (n=2141) Police/fire naloxone (n=645) 52% 48% 23% 24% 21% 26% 5% 11% 3% 5% 9% 7% None Irritable/angry "Dope Sick" Vomiting Combative Other Program data 2008-2014 Other = confused, disoriented, headache, aches and chills, cold, crying, diarrhea, happy, miserable

Help-seeking (calling 911 or EMS present) by people reporting rescues with MDPH naloxone 34% 32% 37% 37% 42% 46% 26% 2007/8 2009 2010 2011 2012 2013 2014 Program data

Implementing OEND in MMT and detox Model Advantages Disadvantages 1. Staff provide OEND onsite 2. Outside staff provide OEND on-site 3. OE provided onsite, naloxone received offsite 4. Outside staff recruit near MMT or detox Good access to OEND OD prevention integrated OD prevention integrated Interagency cooperation Low burden on staff OD prevention integrated Interagency cooperation Confidential access to OD prevention Patients may not disclose risk Community OEND program needed Increased patient burden to get naloxone OD prevention not reenforced in treatment Not all patients reached Among 29 MMT and 93 detox staff who received OEND, 38% and 45% respectively reported witnessing and overdose in their lifetime. Walley et al. JSAT 2013; 44:241-7.

Challenges for community programs Naloxone cost is increasing, funding is minimal Missing people who don t identify as drug users, but have high risk Agencies are CBOs which target IDU, people w/ substance use disorders, HIV prevention Opportunities for prescription naloxone Co-prescribe naloxone with opioids for pain Co-prescribe with methadone/ buprenorphine for addiction Insurance should fund this Increase patient, provider & pharmacist awareness Universalize overdose risk

Models for Prescribing Naloxone Prescriber writes prescription Patient fills at pharmacy Prescriber writes prescription and dispenses prepackaged kit Pharmacy provides naloxone directly to customer Setting: clinic with insured patients Pharmacies alerted to prescribing plans May need to have atomizers on-site for intranasal formulation Consider providing informational brochure Setting: medical care with resources to have and maintain kits on-site Without prescriber contact under a collaborative practice agreement (CPA) or standing order Encourage naloxone co-prescribing 20

Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists Go to prescribetoprevent.org Alexander Y. Walley, MD, MSc Boston University School of Medicine Jeffrey Bratberg, PharmD, BCPS University of Rhode Island College of Pharmacy Corey Davis, JD, MSPH The Network for Public Health Law

Partnerships between addiction treatment programs and retail pharmacies A large pharmacy chain with 87 stores in Massachusetts ready to stock and fill naloxone via prescription or pharmacy standing order Dispensed 487 naloxone rescue kits from 58 stores 12/2014 6/2015 68% (333) of the rescue kits were dispensed form 1 store This store has an agreement with a residential detox program to fill naloxone rescue kits upon release 140 120 Pharmacy A All others 100 80 60 40 20 0 des.14 jan.15 feb.15 mar.15 apr.15 mai.15 jun.15 Prescriber log data

Thank you awalley@bu.edu